AMAsmita Mukherjee

Asmita Mukherjee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Asmita Mukherjee has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Nanostructured lipopeptide-based membranomimetics for stabilizing bacteriorhodopsin

    by Arun Bahadur Gurung, Kasturee Chakraborty, Snehasish Ghosh, Somnath Jan, Paramita Gayen, Abhijit Biswas, Argha Mario Mallick, Monjuri Hembram, Archana Tripathi, Asmita Mukherjee, et al.

    Engineered lipopeptide-based facial detergents having a linear unstructured or cyclic (β-turn) conformation can stabilize the model integral membrane protein, bacteriorhodopsin.


  • Emerging Approaches for Enabling RNAi Therapeutics

    by Argha M. Mallick, Archana Tripathi, Sukumar Mishra, Asmita Mukherjee, Chiranjit Dutta, Ananya Chatterjee, Rituparna Sinha Roy

    RNA interference (RNAi) is a primitive evolutionary mechanism developed to escape incorporation of foreign genetic material. siRNA has been instrumental in achieving the therapeutic potential of RNAi by theoretically silencing any gene of interest in a reversible and sequence‐specific manner. Extrinsically administered siRNA generally needs a delivery vehicle to span across different physiological barriers and load into the RISC complex in the cytoplasm in its functional form to show its efficacy. This review discusses the designing principles and examples of different classes of delivery vehicles that have proved to be efficient in RNAi therapeutics. We also briefly discuss the role of RNAi therapeutics in genetic and rare diseases, epigenetic modifications, immunomodulation and combination modality to inch closer in creating a personalized therapy for metastatic cancer. At the end, we present, strategies and look into the opportunities to develop efficient delivery vehicles for RNAi which can be translated into clinics.